NASDAQ:MLYS Mineralys Therapeutics (MLYS) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free MLYS Stock Alerts $11.36 -0.07 (-0.61%) (As of 04:28 PM ET) Add Compare Share Share Today's Range$11.29▼$11.6750-Day Range$10.75▼$16.1552-Week Range$5.85▼$17.70Volume53,781 shsAverage Volume158,086 shsMarket Capitalization$563.80 millionP/E RatioN/ADividend YieldN/APrice Target$33.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Mineralys Therapeutics alerts: Email Address Mineralys Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside194.9% Upside$33.50 Price TargetShort InterestBearish4.82% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$7.50 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.44) to ($3.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.18 out of 5 starsMedical Sector524th out of 909 stocksPharmaceutical Preparations Industry238th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingMineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMineralys Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.82% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Mineralys Therapeutics has recently increased by 1.00%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldMineralys Therapeutics does not currently pay a dividend.Dividend GrowthMineralys Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLYS. Previous Next 2.6 News and Social Media Coverage News SentimentMineralys Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Mineralys Therapeutics this week, compared to 1 article on an average week.Search Interest7 people have searched for MLYS on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Mineralys Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mineralys Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,499,992.00 in company stock and sold $0.00 in company stock.Percentage Held by Institutions84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($2.44) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mineralys Therapeutics is -5.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mineralys Therapeutics is -5.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMineralys Therapeutics has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Mineralys Therapeutics Stock (NASDAQ:MLYS)Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Read More MLYS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLYS Stock News HeadlinesApril 2, 2024 | msn.comGoldman starts Mineralys at buy, cites upcoming drug dataMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Mineralys Therapeutics Amid Positive Clinical and Strategic DevelopmentsApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 22, 2024 | finance.yahoo.comMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | msn.comMineralys Therapeutics files for $500M mixed shelf offeringMarch 21, 2024 | finance.yahoo.comMineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...March 21, 2024 | seekingalpha.comMineralys Therapeutics, Inc. 2023 Q4 - Results - Earnings Call PresentationMarch 21, 2024 | globenewswire.comMineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 20, 2024 | finance.yahoo.comMLYS Jun 2024 12.500 callMarch 20, 2024 | finance.yahoo.comMLYS Sep 2024 30.000 callMarch 20, 2024 | benzinga.comMineralys Therapeutics Earnings PreviewMarch 18, 2024 | msn.comMineralys Therapeutics Set to Release Q4 and Full-Year 2023 Financial Results, Eyes on Future Growth ProspectsMarch 18, 2024 | seekingalpha.comMineralys Therapeutics: A Story To Keep An Eye OnMarch 16, 2024 | finance.yahoo.comMLYS Apr 2024 15.000 callMarch 16, 2024 | finance.yahoo.comMLYS Mar 2024 20.000 callMarch 13, 2024 | globenewswire.comMineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024March 4, 2024 | benzinga.comMineralys Therapeutics Stock (NASDAQ:MLYS) Dividends: History, Yield and DatesFebruary 9, 2024 | seekingalpha.comMineralys: 2nd Half 2024 Hypertension Data ReadoutFebruary 9, 2024 | bizjournals.comMineralys Therapeutics set to raise $120M from investors to develop treatment for high blood pressureFebruary 9, 2024 | msn.comMineralys Therapeutics Equity Sales: Investor Impact ReportFebruary 9, 2024 | msn.comMineralys Therapeutics Announces Strategic Purchase AgreementFebruary 8, 2024 | msn.comMineralys Therapeutics stock jumps on $120M private placement financingFebruary 8, 2024 | finance.yahoo.comMineralys Therapeutics Announces $120 Million Private Placement FinancingJanuary 29, 2024 | finance.yahoo.comMineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology ConferenceJanuary 17, 2024 | finance.yahoo.comMineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should KnowJanuary 6, 2024 | seekingalpha.comMLYS Mineralys Therapeutics, Inc.See More Headlines Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/24/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MLYS CUSIPN/A CIK1933414 Webwww.mineralystx.com Phone888-378-6240FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$33.50 High Stock Price Target$37.00 Low Stock Price Target$30.00 Potential Upside/Downside+187.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,900,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.48% Return on Assets-25.52% Debt Debt-to-Equity RatioN/A Current Ratio23.76 Quick Ratio23.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.87 per share Price / Book1.98Miscellaneous Outstanding Shares49,630,000Free FloatN/AMarket Cap$577.69 million OptionableOptionable Beta2.35 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Jon Congleton (Age 61)CEO & Director Comp: $428.87kMr. Adam Scott Levy (Age 46)CFO & Secretary Comp: $409.17kDr. David M. Rodman M.D. (Age 69)Chief Medical Officer Comp: $423.66kDr. Brian Taylor Slingsby M.D. (Age 47)M.P.H., Ph.D., Founder & Executive Chairman Ms. Cindy BerejikianExecutive Vice President of OperationsMs. Sarah FosterVice President of Human ResourcesDr. Robert McKean Ph.D.Senior Vice President of CMCMs. Danielle BradburySenior Vice President of Quality AssuranceMr. Jeffrey N. FellowsSenior Vice President of Regulatory AffairsMs. Jessica IbbitsonSenior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsVerve TherapeuticsNASDAQ:VERVOlema PharmaceuticalsNASDAQ:OLMACureVacNASDAQ:CVACNuvation BioNYSE:NUVBPhibro Animal HealthNASDAQ:PAHCView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 4,099 shares on 3/22/2024Ownership: 0.010%Catalys Pacific LLCBought 9,194,579 shares on 2/14/2024Ownership: 22.371%Sectoral Asset Management Inc.Sold 235,153 shares on 2/14/2024Ownership: 1.473%Pale Fire Capital SEBought 34,743 shares on 2/14/2024Ownership: 0.085%Tower Research Capital LLC TRC Sold 7,181 shares on 2/13/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions MLYS Stock Analysis - Frequently Asked Questions Should I buy or sell Mineralys Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mineralys Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MLYS shares. View MLYS analyst ratings or view top-rated stocks. What is Mineralys Therapeutics' stock price target for 2024? 3 Wall Street analysts have issued twelve-month target prices for Mineralys Therapeutics' stock. Their MLYS share price targets range from $30.00 to $37.00. On average, they predict the company's stock price to reach $33.50 in the next year. This suggests a possible upside of 194.9% from the stock's current price. View analysts price targets for MLYS or view top-rated stocks among Wall Street analysts. How have MLYS shares performed in 2024? Mineralys Therapeutics' stock was trading at $8.60 at the beginning of 2024. Since then, MLYS stock has increased by 32.1% and is now trading at $11.36. View the best growth stocks for 2024 here. When is Mineralys Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our MLYS earnings forecast. How were Mineralys Therapeutics' earnings last quarter? Mineralys Therapeutics, Inc. (NASDAQ:MLYS) issued its quarterly earnings results on Thursday, March, 21st. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.24. What ETFs hold Mineralys Therapeutics' stock? ETFs with the largest weight of Mineralys Therapeutics (NASDAQ:MLYS) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS) and Virtus LifeSci Biotech Clinical Trials ETF (BBC) and When did Mineralys Therapeutics IPO? Mineralys Therapeutics (MLYS) raised $180 million in an IPO on Friday, February 10th 2023. The company issued 12,000,000 shares at $14.00-$16.00 per share. How do I buy shares of Mineralys Therapeutics? Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MLYS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.